Skip to main content

Viloxazine (Qelbree): A Faster Strattera?

On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/

 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Teens on the couch

Motivational Interviewing for Teens: Focus on Marijuana

Lots of teens use marijuana and many of these kids suffer significant harm from it. But just telling teens to stop is unlikely to work. This case based webinar will help you learn how to help teens reduce their use and the problems it brings.

Foundations for a Peaceful World

This week we are launching a new book at the United Nations General Assembly with the voices of multiple countries impacted by armed conflict, some on different sides in the same region, all committed to helping all the children.

Recognizing and Treating Psychosis in Autism

Is it autism, psychosis or both? Autistic traits and psychotic symptoms can look alike. How common is psychosis in autism? Can we differentiate co-occurring autistic traits from psychotic symptoms? Dr. Kristin Cadenhead helps us sort it out.